الاقتصادية
Oil prices rise 3% as U.S.-Iran tensions escalate
Decline in Basic Metal Prices Amid Fears of Iran War
TASI Index Increases by 0.36% at Midday Trading Driven by Three Leading Sectors
Riyadh Air Considers Buying 30 Additional Boeing 787 Aircraft
TASI Index Closes Down 0.16% with Over 4 Billion Riyals in Liquidity
المصدر: الاقتصادية
29 Minsجاهز للتشغيل
جاهز للتشغيل
AstraZeneca announced the signing of a deal with Dizal Pharmaceuticals valued at $600 million upfront to acquire worldwide rights to the drug Senvoldinib, used in the treatment of non-small cell lung cancer. The medication has been approved in the United States and China, and it has shown promising results, with an average progression-free survival of 10.3 months compared to 7.5 months with chemotherapy. The agreement includes AstraZeneca's global development and marketing rights, with an initial payment and potential earn-outs totaling up to $900 million tied to commercial success.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading